In the KEYNOTE-012 study, which investigated pembrolizumab in pretreated, recurrent/metastatic HNSCC the overall response rate of patients with p16 positive disease was 24% compared to 16% in patients with p16 negative tumors [49]. Here, CDKN2A is linked to head and neck squamous cell carcinoma.